Health
AnPac Bio-Medical Science Announces US$5 Million Private Placement
NEW YORK, March 6, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) ("AnPac Bio," the "Company" or "we"), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business ...
2023-03-06 21:30
3353
Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001
SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today...
2023-03-06 21:00
2125
HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis
* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China for the treatment of myasthenia gravis SEOUL, South Korea, March 6, 2023 /PRNewswire/ -- HanAll Biopharma...
2023-03-06 20:00
1586
Assure Tech Launches a New Platform - Comprehensive Health Solution
HANGZHOU, China, March 6, 2023 /PRNewswire/ -- With the rapid development of the social economy and the continuous improvement in people's living standard, pets, especially cats and dogs, have gradually become important family members in modern times.World wide, strong demand for pet-related prod...
2023-03-06 18:47
1335
Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 6, 2023 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2023-03-06 14:27
2226
Confirmatory clinical trial of Liwen RF™ ablation system in China concluded
HANGZHOU, China, March 6, 2023 /PRNewswire/ -- On March 3, Venus Medtech ( Hangzhou) Inc. (Venus Medtech, 2500.HK), trailblazer in structural heart therapies worldwide, announced that the Liwen RF™ ablation system developed by the Company has successfully enrolled one patient at West China Hospita...
2023-03-06 07:29
2601
US proteomics sector set for shake-up as new IonOpticks tech unveiled
IonOpticks to introduce the TS, a fully integrated column heating and interface solution for Thermo Scientific users MELBOURNE, Australia, March 3, 2023 /PRNewswire/ -- IonOpticks, a producer of high-performance chromatography solutions for the global research community, will introduce the new T...
2023-03-03 22:00
3832
Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published
SUZHOU, China, March 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announces that the study ...
2023-03-03 14:56
2777
AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL®, the Progressive Extended Depth-of-Focus IOL
SHANGHAI, March 3, 2023 /PRNewswire/ -- AffaMed Technologies ("AffaMed"), a joint venture established between AffaMed Therapeutics and SIFI S.p.A., today announced the completion of the first patient implantation in the Registrational Clinical Trial of its MINI WELL® progressive Extended Depth-o...
2023-03-03 09:00
3855
Medidata Drives Diversity in Clinical Trials, Passing 30,000 Studies and 9 Million Participants
Unprecedented industry milestones achieved with continuous innovation
supporting the digital transformation of life sciences
SINGAPORE, March 3, 2023 /PRNewswire/ -- Known for its ground-breaking
technological innovations in clinical trials,Medidata
2023-03-03 09:00
2804
Neurophet to unveil new technology for analyzing ARIA side effect at ECR 2023
* Introducing brain imaging analysis solutions including Neurophet AQUA and Neurophet SCALE PET * Unveiling technology to analyze and monitor ARIA, side effect of anti-amyloid antibody drug for Alzheimer's disease SEOUL, South Korea, March 2, 2023 /PRNewswire/ -- Neurophet, an artificial inte...
2023-03-02 22:00
2202
Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy
SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd.
(Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on
February 27, 2023, a strategic collaboration in gene and cell therapy pipelines
to expedite the development of innovative therapeutics.
2023-03-02 20:00
2088
AIRS Medical Applauded by Frost & Sullivan for Reducing MRI Equipment's Exam Wait Times with Its SwiftMR™ Technology
SwiftMR™ improves image quality of MRI scans, enables easy installation and use, andadapts to healthcare providers' existing scanners because it is a stand-alone offering. SAN ANTONIO, March 2, 2023 /PRNewswire/ -- Recently, Frost & Sullivan researched the artificial intelligence (AI)-powered ma...
2023-03-02 20:00
2363
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
LONDON and HONG KONG, March 2, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB') to provide strategic input based on their scientific knowledge and c...
2023-03-02 20:00
2797
Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376
SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shanghai Allist Pharmaceuticals Co., Ltd., ("Allist" hereafter) for the further ...
2023-03-02 19:15
3277
Sanyou Biopharmaceuticals opens Cambridge MA, US office, expanding its business outreach to a central hub of biotech network
CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech sta...
2023-03-02 18:00
1677
111 to Announce Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results- Conference Call to Follow
SHANGHAI, March 2, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2023-03-02 15:35
2448
ExoCoBio obtained 2 GMP Licenses for Exosome Biopharmaceuticals from Korea MFDS and for Hyaluronic Acid (HA) Dermal Fillers from Brazil ANVISA
* ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. * Cellosome™ HA fillers are expected to be approved in 2023. * ExoCoBio has all 3 types of GMP clearance for pharmaceuticals, medical devices, & cosmetics. SEOUL, South Korea, March 2, 2023 /PRNewswire/ -...
2023-03-02 14:09
3673
Robert Walters China Salary Survey 2023: Easing of Epidemic Control: Recruitment Market Stabilises, Data Security and Compliance Talent being Key Recruitment Targets
SHANGHAI, March 2, 2023 /PRNewswire/ -- The government has announced the optimisation of the epidemic control measures, recruitment market is expected to rebound and gradually stabilise, according to theSalary Survey 2023 released byRobert Walters, one of the world-leading specialist professional...
2023-03-02 14:00
2326
DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Debiopharm obtains global rights from Novo Nordisk for the development of their
ubiquitin-specific protease 1 (USP1) inhibitor
LAUSANNE, Switzerland, March 2, 2023 /PRNewswire/ -- Debiopharm (
www.debiopharm.com
2023-03-02 09:00
2848
Week's Top Stories
Most Reposted
Thailand Tops 2024 Consumer Review Awards by Agoda
[Picked up by 329 media titles]
2024-09-26 11:00
WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
[Picked up by 314 media titles]
2024-09-26 00:00
Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
[Picked up by 312 media titles]
2024-09-23 13:37
Circles Partners with Telkomsel, Providing an Advanced Software-as-a-Service (SaaS) Platform to Enhance Customer Digital Experience
[Picked up by 300 media titles]
2024-09-27 10:00RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
[Picked up by 294 media titles]
2024-09-23 22:00
Most Read
WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
2024-09-26 00:00
9768
Thailand Tops 2024 Consumer Review Awards by Agoda
2024-09-26 11:00
8736
RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
2024-09-23 22:00
6962